ANASTROZOLE

Post-LOE

anastrozole tablets

ANDAORALTABLET
Approved
Nov 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Aromatase Inhibitors

Pharmacologic Class:

Aromatase Inhibitor

Clinical Trials (5)

NCT05896566Phase 2Completed

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Started Jan 2024
231 enrolled
Breast Cancer
NCT05549505Phase 2Completed

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Started Feb 2023
152 enrolled
Breast Cancer
NCT05190094Phase 2Recruiting

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

Started Dec 2022
80 enrolled
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
NCT04711252Phase 3Active Not Recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Started Jan 2021
1,370 enrolled
ER-Positive HER2-Negative Breast Cancer
NCT04553770Phase 2Recruiting

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Started Oct 2020
88 enrolled
Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more